Zhifei Biological
智飞生物
Executive Summary
Zhifei Biological is a Chongqing-based vaccine developer with strong revenue of ~$3.2B and healthy profitability, making it a potentially attractive BD partner. The company shows active pipeline development with recent approvals for mpox vaccine trials and COVID-19 mRNA vaccine studies, plus expansion into diabetes with insulin products. BIOSECURE risk appears low given its clear status, though standard due diligence on government relationships is recommended.
Structure: Listed directly on Shenzhen Stock Exchange (300122.SZ) with controlling shareholder conducting share pledging activities as of March 2026. Limited visibility into subsidiary structure from available data, requiring deeper due diligence to map potential VIE arrangements or holding company layers typical of Chinese biotech firms.
Latest Financials
Revenue: 22786387624.05, Net Profit: 2121744962.2. Source: East Money (300122)
Period: 2024-09-30 | Source: eastmoney
Corporate Events
智飞生物：关于公司控股股东部分股份质押的公告
CNINFO announcement for Zhifei Biological (300122.SZ)
智飞生物：关于改良型安卡拉痘苗病毒（MVA）猴痘减毒活疫苗获得临床试验批准通知书的公告
CNINFO announcement for Zhifei Biological (300122.SZ)
智飞生物：关于德谷胰岛素注射液申请生产注册获得受理的公告
CNINFO announcement for Zhifei Biological (300122.SZ)
智飞生物：关于取得发明专利证书的公告
CNINFO announcement for Zhifei Biological (300122.SZ)
智飞生物：关于HK.3-JN.1新型冠状病毒mRNA疫苗获得临床试验批准通知书的公告
CNINFO announcement for Zhifei Biological (300122.SZ)
Zhifei Biological Financial Report
Revenue: 22786387624.05, Net Profit: 2121744962.2. Source: East Money (300122)
BIOSECURE Risk
Company has clear BIOSECURE status and is not designated under BCC categories, suggesting limited direct exposure to restricted entities
Key Exposures:
- •Controlling shareholder share pledging activities
- •Potential undisclosed government research collaborations
- •Supply chain dependencies on restricted entities
Mitigation: No specific BIOSECURE mitigation measures visible from public disclosures
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent out-licensing deals visible in available data; appears to be in development/regulatory phase for key assets
Approach: Approach with focus on vaccine platform technologies and emerging infectious disease capabilities; assess insulin program for potential US partnership opportunities
Red Flags
- ⚠Controlling shareholder share pledging activity indicates potential financial stress
- ⚠Limited transparency on subsidiary structure and key management
- ⚠Rapid expansion across multiple therapeutic areas may indicate resource constraints
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 6
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.